Anti-Phospholipase A₂ Receptor antibodies in the diagnosis of idiopathic Membranous Nephropathy

Guida Meneses (1), Helena Viana (1,2), Maria C. Santos (3), Carina Ferreira (1), Joaquim Calado (1), Fernanda Carvalho (2), Francisco Remédio (1) Fernando Nolasco (1)

(1) - Curry Cabral Hospital, Nephrology service, Lisbon, Portugal (2) - Curry Cabral Hospital, Renal Morphology laboratory, Lisbon, Portugal (3) - Curry Cabral Hospital, Immunology laboratory, Lisbon, Portugal

Introduction and objectives

- The Phospholipase A₂ Receptor was identified as autoantigen in the idiopathic membranous nephropathy (iMN).
- Circulating anti-phospholipase A_2 receptor antibodies (anti-PLA₂R) has been described in 70% to 80% of the patients with iMN ¹ but not in patients with secondary membranous nephropathy or other glomerular diseases.
- The goal of this study was to evaluate the sensitivity and specificity of the assay for anti-PLA₂R in the diagnosis of iMN.

Population and methods

- Anti-PLA₂R IgG, Elisa and immunofluorescence test were used to detect circulating anti-PLA₂R.
- This test was applied to 53 patients who had already been submitted to a kidney biopsy between November 2011 and May 2013.

Membranous Nephropathy (MN) n=38 | Idiopathic MN (iMN) n=33 | Secondary MN (sMN) n=5 | Other Glomerular Diseases (other GD) n=15


ROC curve was used to determine the sensitivity and specificity of the assay.

Results

• Anti-PLA₂R was only positive in patients with iMN.

	iMN	sMN	other GD
Anti-PLA2R +	19	0	0
Anti-PLA2R -	14	5	15

- The sensitivity was 57,6% (CI 39,2-74,5) and specificity 100% (CI 47,8-100), AUC 0,788; P<0,0001 for the detection of iMN.
- 71,4% (n=10) of the 14 iMN patients that tested negative for anti-PLA₂R were in partial or complete remission.



- Anti-PLA₂R became negative in 2 patients with iMN after treatment with cyclosporine.
- Anti-PLA₂R became positive in 1 patient with relapse.

Conclusion

- The detection of anti-PLA₂R in the studied population had a specificity of 100% for the iMN diagnosis. Successful prior treatment can contribute to the low sensitivity (57,6%).
- The usefulness of this assay as a marker of treatment response should be evaluated.

References

- 1. Hanna Debiec, Pierre Ronco, "PLA $_2$ R autoantibodies and PLA $_2$ R glomerular deposits in membranous nephropathy" NEJM, February 2011, 689-690.
- 2 . Stanescu et all, "Risk HLA-DQA1 and PLA2R1 alleles in Idiopathic membranous nephropathy", NEJM, February 2011, 616-626.

